NEOGENOMICS INC's ticker is NEO and the CUSIP is 64049M209. A total of 283 filers reported holding NEOGENOMICS INC in Q1 2022. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $13,090,437 | +28.2% | 1,416,714 | +19.4% | 0.00% | 0.0% |
| Q3 2022 | $10,213,303 | +17.5% | 1,186,214 | +11.2% | 0.00% | +50.0% |
| Q2 2022 | $8,690,321 | -12.7% | 1,066,297 | +30.1% | 0.00% | 0.0% |
| Q1 2022 | $9,954,920 | -64.4% | 819,335 | 0.0% | 0.00% | -66.7% |
| Q4 2021 | $27,956,000 | -24.6% | 819,335 | +6.6% | 0.01% | -25.0% |
| Q3 2021 | $37,091,000 | +1.5% | 768,878 | -5.0% | 0.01% | 0.0% |
| Q2 2021 | $36,555,000 | -16.9% | 809,280 | -11.2% | 0.01% | -20.0% |
| Q1 2021 | $43,977,000 | -13.4% | 911,813 | -3.4% | 0.01% | -16.7% |
| Q4 2020 | $50,808,000 | +57.7% | 943,690 | +8.0% | 0.01% | +33.3% |
| Q3 2020 | $32,228,000 | +23.7% | 873,626 | +3.9% | 0.01% | +12.5% |
| Q2 2020 | $26,059,000 | +7.3% | 841,140 | -4.3% | 0.01% | -11.1% |
| Q1 2020 | $24,276,000 | -1.7% | 879,259 | +4.2% | 0.01% | +28.6% |
| Q4 2019 | $24,693,000 | +310.0% | 844,190 | +168.0% | 0.01% | +250.0% |
| Q3 2019 | $6,022,000 | – | 314,974 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kopp Family Office, LLC | 1,785,605 | $86,138,000 | 34.19% |
| PERKINS CAPITAL MANAGEMENT INC | 157,750 | $7,610,000 | 4.71% |
| Blue Water Life Science Advisors, LP | 222,222 | $10,719,000 | 3.49% |
| First Light Asset Management, LLC | 1,055,960 | $50,940,000 | 3.36% |
| Ranger Investment Management | 810,956 | $39,121,000 | 2.09% |
| Bullseye Asset Management LLC | 108,054 | $5,212,000 | 1.81% |
| Lombard Odier Asset Management (Switzerland) SA | 584,281 | $28,186,000 | 1.75% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 998,858 | $48,185,000 | 1.67% |
| EMERALD ADVISERS, LLC | 904,298 | $43,623,000 | 1.58% |
| Soleus Capital Management, L.P. | 190,556 | $9,192,000 | 1.43% |